About Sutro Biopharma

At Sutro Biopharma we have pioneered a compelling and unique way of discovering, developing and manufacturing therapeutics. Our focus is aimed primarily on next generation cancer therapeutics and autoimmune disease — Antibody Conjugates, Bispecific Antibodies and cytokine derivatives. Unconstrained by traditional methods of cell-based discovery, we can design and develop targeted medicines by innovating outside the constraints of the cell.

Learn More


Our technology enables us to iteratively discover and test molecules in a rapid cycle of weeks rather than months, to rapidly identify the optimal molecule designed for safety and potency.

Learn More


Sutro Biopharma is working independently and with partners to develop novel cancer therapies, including antibody-drug conjugates, bispecific antibodies, and antibody-based therapeutics targeting immuno-oncology pathways.

Learn More

Recent News


Sutro and The Leukemia & Lymphoma Society Partner on Lymphoma and Multiple Myeloma Treatment

Expand Clinical Research on Patients with Progressive Disease SOUTH SAN FRANCISCO, August 13, 2018– Sutro Biopharma, Inc.,and TheLeukemia & Lymphoma Society® , or.. Read More →

Sutro Biopharma Announces $85.4 Million Series E Round

Funds Novel Cancer Treatments, Early-Stage Programs & Platform-Technology Advancement A Boost for Next-Generation Protein Therapies SOUTH SAN FRANCISCO, July 26, 2018 – Sutro.. Read More →


At Sutro, collaboration drives how we achieve results. By putting the goals of the Company first, we aim to make a difference both as individuals and as part of a team.

Learn More